As BRCA1 suppresses tumor growth, we hypothesized that full BRCA1 dosage might inhibit tumorigenesis, while BRCA1 suppression by FGFR2 signaling could weaken this inhibition. The gene discussed is BRCA1; the disease is neoplasm.